FMOLHS P&T - 2022

February

(System P&T)

Kcentra will remain formulary with the following fixed dosing strategy

• Warfarin related life-threatening bleeding-1500 units
• Anti-Xa related life-threatening bleeding-2000 units

Idarucizumab (Praxbind) added to system formulary

• Each market to determine formulary status

Andexanet alfa (Andexxa) reviewed and NOT approved for formulary addition

Drug Class Reviews

• Antidepressants - no autosubstitutions 
  • Noradrenergic and Specific Serotonin Reuptake Inhibitors
  • Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs)
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
• Calcium Channel Blockers-restrictions removed from clevidipine
• Benzodiazepines
• Diuretics, Thiazides
• Beta Blocker therapeutic substitution approval-Bisoprolol to metoprolol

January

(System P&T)

Oxacillin added to formulary, nafcillin removed from formulary.

Meropenem dose buttons added in Epic

Drug classes reviewed:

• Bone Resorption Inhibitors
• P2Y12 Inhibitors

Calcitonin restriction criteria discussed and approved